Mankind Pharma receives GST order, expects no material financial impact.
Mankind Pharma received a GST order levying a penalty of ₹15.32 crore for FY19-23. The company disputes the order, citing reconciliation differences in GST returns, and expects no material financial or operational impact. An appeal will be filed.
Despite the penalty amount, the company's assessment indicates no material impact on its financials or operations, and it plans to appeal the order.
The company has received a significant penalty order from the GST authorities, but it believes the order is not tenable and expects no material impact, intending to appeal. This neutralizes the negative aspect of the penalty.
Mankind Pharma Limited has received an order on December 10, 2025, from the Office of the Principal Commissioner, Central GST & Central Excise, Patna. The order, issued by the Joint Commissioner, pertains to the financial years 2018-19 to 2022-23 and levies a penalty of ₹15,31,70,825 (15.32 crore).
The alleged violation relates to the disallowance of Input Tax Credit (ITC) due to reconciliation differences in GST returns.
Mankind Pharma stated that based on their assessment of the facts and prevailing law, the order is not tenable. The company believes it has sufficient grounds to contest the order and does not anticipate any material impact on its financials, operations, or other activities. The company plans to file a necessary appeal with the appellate authority.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under regulatory impact. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.